Facilities

Manufacturing Facilities Setup Taj Pharma Group

Taj Pharma Group has established a diversified pharmaceutical manufacturing infrastructure in India covering oral solid dosages, sterile injections, oncology products, beta-lactam antibiotics, large-volume parenterals, topical formulations, nutraceuticals, and food supplements. Our manufacturing setup is organized across specialized facilities, with each plant or production block designed around particular dosage forms, technologies, and pharmaceutical product categories.

Our manufacturing network includes facilities at Sarigam GIDC, Kalgam Village in Valsad, and Vadgas, Viramgam near Ahmedabad. This multi-facility structure allows us to support different manufacturing requirements while maintaining dedicated capabilities for conventional pharmaceuticals, sterile products, cytotoxic medicines, beta-lactam products, IV solutions, and nutritional formulations.

Taj Pharma Manufacturing Facilities in India

Our manufacturing infrastructure encompasses a broad range of pharmaceutical production capabilities. The facilities described within our manufacturing setup include:

  • Sarigam GIDC Manufacturing Plant – EU GMP and PICs design formulations plant
  • Kalgam Village, Valsad Injections Plant – liquid ampoules, liquid vials, dry injections, and small-volume parenterals
  • Vadgas, Viramgam Block Unit 1 – general liquid injections, dry powders, lyophilized injections, and prefilled syringes
  • Vadgas, Viramgam Block Unit 2 – oncology and cytotoxic formulations
  • Vadgas, Viramgam Unit 3 – beta-lactam tablets, capsules, dry powder injections, and dry suspensions
  • Large Volume Parenterals Plant – IV solutions using PVC bottle formats
  • Vadgas, Viramgam Block Unit 5 – tablets and capsules, with US FDA approval referenced in the supplied facility information
  • Vadgas, Viramgam Unit 6 – nutraceuticals and food supplements

This specialized manufacturing setup provides a foundation for producing pharmaceutical products across multiple therapeutic and dosage-form categories.

Sarigam GIDC Manufacturing Plant

The Sarigam GIDC Manufacturing Plant is one of the principal facilities within the Taj Pharma manufacturing network. The supplied facility information identifies it as an EU GMP and PICs design formulations plant equipped to manufacture multiple pharmaceutical dosage forms.

The stated production capacities include:

Dosage Form / Product CategoryStated Capacity
Tablets120 million per month
Capsules40 million per month
Dry Blended Powders / Granules20 million per month
Effervescent Tablets20 million per month
Oral Jelly60 million per month
Creams / Ointments40 million per month
Oral Sachets3 million per month

The diversity of production formats makes the Sarigam facility suitable for a broad range of pharmaceutical formulation requirements. In addition to conventional tablets and capsules, the facility is described as supporting dry blended powders and granules, effervescent tablets, oral jelly, topical creams and ointments, and oral sachets.

The stated capacity of 120 million tablets per month and 40 million capsules per month provides substantial oral-solid manufacturing capability within the overall Taj Pharma manufacturing network.

Kalgam Village, Valsad Injections Manufacturing Plant

The Kalgam Village, Valsad Injections Plant is dedicated to injectable pharmaceutical manufacturing. The facility is described as supporting general small-volume parenterals as well as liquid ampoules, liquid vials, and dry powder injections.

The stated shift-wise production capacities are:

  • Liquid Ampoule Injection: 2.5 lakh units per shift
  • Liquid Vial Injection: 2.5 lakh units per shift
  • Dry Injection: 3.5 lakh units per shift
  • Small Volume Parenterals: 4.5 lakh units per shift

Injectable manufacturing requires specialized processes, equipment, environmental controls, quality systems, and testing appropriate to sterile pharmaceutical products. The Kalgam facility therefore represents an important component of our injectable manufacturing infrastructure.

Its combination of liquid and dry injectable capabilities provides flexibility for pharmaceutical products requiring different presentation and formulation technologies.

Vadgas, Viramgam – Block Unit 1

Vadgas, Viramgam Block Unit 1 is described as a specialized facility for general injectable products and associated pharmaceutical technologies.

The manufacturing categories include:

  • General liquid injections
  • General dry powder injections
  • Lyophilized injections
  • Prefilled syringes

Lyophilized products are produced using freeze-drying technology, which can be used for pharmaceutical products where the formulation benefits from being maintained in a dry, stable form before administration or reconstitution.

The unit’s prefilled-syringe capability provides another specialized pharmaceutical presentation, while liquid and dry powder injection capabilities broaden the range of injectable products that can be manufactured.

Vadgas, Viramgam – Block Unit 2 Oncology Manufacturing

Our Vadgas, Viramgam Block Unit 2 is dedicated to oncology manufacturing, with a focus on cytotoxic pharmaceutical products.

The supplied manufacturing information identifies the following categories:

  • Cytotoxic tablets
  • Cytotoxic capsules
  • Cytotoxic liquid injections
  • Cytotoxic dry powder injections
  • Cytotoxic lyophilized injections
  • Suspensions

Oncology manufacturing requires specialized approaches to product handling, segregation, process control, occupational protection, environmental management, and quality assurance. A dedicated oncology manufacturing block allows these requirements to be addressed within a specialized production environment.

The availability of both oral and injectable oncology dosage forms enables the facility to support different pharmaceutical delivery formats.

Vadgas, Viramgam Unit 3 – Beta Lactam Manufacturing

Vadgas, Viramgam Unit 3 is dedicated to beta-lactam pharmaceutical manufacturing. Beta-lactam antibiotics represent an important category of antibacterial medicines.

The facility is described as manufacturing:

  • Beta-lactam tablets
  • Beta-lactam capsules
  • Beta-lactam dry powder injections
  • Beta-lactam dry suspensions

Dedicated manufacturing arrangements are particularly important for pharmaceutical categories requiring appropriate segregation and controlled handling. The specialized Unit 3 setup provides a dedicated environment for beta-lactam dosage forms.

The combination of oral and injectable beta-lactam products allows the manufacturing facility to support different pharmaceutical presentation requirements.

Large Volume Parenterals Manufacturing Plant

Taj Pharma’s Large Volume Parenterals (LVP) manufacturing setup is focused on IV solutions supplied in PVC bottle formats. The supplied information describes aseptic filling of aqueous solutions into LVP bottles.

The stated production capacities include:

FFS Bottle Manufacturing

The Form-Fill-Seal (FFS) bottle line has a stated capacity of:

10 million bottles per day

FFS technology integrates container formation, filling, and sealing within a controlled manufacturing operation and is particularly suited to high-volume pharmaceutical packaging.

Euro Cap Bottle Manufacturing

The Euro Cap bottle line has a stated capacity of:

5 million bottles per day

The combination of these two bottle formats provides a substantial stated manufacturing capacity for large-volume IV solution products.

Vadgas, Viramgam – Block Unit 5

Vadgas, Viramgam Block Unit 5 is focused on the production of tablets and capsules.

The supplied information identifies US FDA approval in connection with tablet and capsule manufacturing at this facility. Such regulatory references should be considered according to the applicable facility documentation and current regulatory status for the specific product and market.

Tablets and capsules remain important pharmaceutical dosage forms because they can accommodate a wide range of active pharmaceutical ingredients and therapeutic applications. A dedicated oral-solid manufacturing facility therefore provides an important component of the broader Taj Pharma manufacturing network.

Vadgas, Viramgam Unit 6 – Nutraceuticals and Food Supplements

Vadgas, Viramgam Unit 6 focuses on nutraceuticals and food supplements.

This facility expands the manufacturing network beyond conventional pharmaceutical dosage forms into nutritional and wellness products. Dedicated production capabilities allow nutraceutical and food-supplement manufacturing activities to be managed according to the applicable product category and regulatory requirements.

Comprehensive Pharmaceutical Manufacturing Capabilities

Our manufacturing setup covers a wide range of pharmaceutical technologies and product formats.

Oral Solid Dosages

Our facilities support:

  • Tablets
  • Capsules
  • Effervescent tablets
  • Dry blended powders
  • Granules
  • Oral sachets
  • Oral jelly

Sterile and Injectable Products

The manufacturing network includes:

  • Liquid ampoule injections
  • Liquid vial injections
  • Dry injections
  • Small-volume parenterals
  • Lyophilized injections
  • Prefilled syringes
  • Large-volume parenterals

Specialized Therapeutic Manufacturing

Dedicated manufacturing capabilities include:

  • Oncology products
  • Cytotoxic formulations
  • Beta-lactam antibiotics

Topical Products

The Sarigam facility is described as supporting:

  • Creams
  • Ointments

Nutraceutical Manufacturing

The Vadgas Unit 6 setup includes:

  • Nutraceutical products
  • Food supplements

This broad manufacturing portfolio allows us to address different pharmaceutical and healthcare product requirements through specialized facilities.

Manufacturing Capacity Across Multiple Dosage Forms

The stated capacities demonstrate the scale and diversity of the manufacturing network.

At Sarigam GIDC, the stated monthly capacity includes 120 million tablets and 40 million capsules, alongside substantial capacities for dry powders, granules, effervescent tablets, oral jelly, creams, ointments, and oral sachets.

The Kalgam facility provides shift-wise injectable manufacturing capacity, while the LVP setup provides stated daily capacities of 10 million FFS bottles and 5 million Euro Cap bottles.

The manufacturing network therefore combines high-volume production with specialized capabilities for technically distinct pharmaceutical categories.

Quality-Focused Pharmaceutical Manufacturing

Our manufacturing facilities are structured around specialized pharmaceutical production requirements. The supplied information references EU GMP, PICs, and US FDA-related capabilities for particular facilities.

Pharmaceutical manufacturing requires systematic control of raw materials, manufacturing processes, equipment, environmental conditions, packaging, documentation, testing, and finished-product release.

Specialized manufacturing units can also provide dedicated production environments for categories requiring specific handling or segregation considerations, such as oncology and beta-lactam products.

Manufacturing Infrastructure for Global Pharmaceutical Supply

The Taj Pharma manufacturing setup is designed to support pharmaceutical production for different market requirements. The combination of multiple manufacturing locations, specialized production blocks, high stated capacities, and diverse dosage-form capabilities creates an infrastructure capable of supporting a broad pharmaceutical portfolio.

From high-volume tablets and capsules to sterile injections, oncology formulations, beta-lactam antibiotics, IV solutions, topical products, and nutraceuticals, the facilities collectively cover a substantial range of pharmaceutical manufacturing requirements.

Taj Pharma Manufacturing Facilities – Key Highlights

FacilityPrimary Manufacturing Focus
Sarigam GIDCTablets, capsules, powders, granules, effervescent tablets, oral jelly, creams, ointments, sachets
Kalgam Village, ValsadLiquid ampoules, liquid vials, dry injections, SVPs
Vadgas Block Unit 1Liquid injections, dry powders, lyophilized injections, prefilled syringes
Vadgas Block Unit 2Oncology and cytotoxic products
Vadgas Unit 3Beta-lactam tablets, capsules, dry injections, dry suspensions
LVP PlantIV solutions, FFS bottles, Euro Cap bottles
Vadgas Block Unit 5Tablets and capsules
Vadgas Unit 6Nutraceuticals and food supplements

Frequently Asked Questions About Taj Pharma Manufacturing

Where are Taj Pharma manufacturing facilities located?

The supplied manufacturing information identifies facilities at Sarigam GIDC, Kalgam Village in Valsad, and Vadgas, Viramgam near Ahmedabad.

What is manufactured at the Sarigam GIDC facility?

The facility is described as manufacturing tablets, capsules, dry blended powders and granules, effervescent tablets, oral jelly, creams, ointments, and oral sachets.

What is the tablet manufacturing capacity at Sarigam?

The stated tablet manufacturing capacity is 120 million tablets per month.

What products are manufactured at the Kalgam Valsad plant?

The facility is described as producing liquid ampoule injections, liquid vial injections, dry injections, and small-volume parenterals.

Which Taj Pharma facility specializes in oncology products?

Vadgas, Viramgam Block Unit 2 is identified as the oncology manufacturing facility, with capabilities covering cytotoxic tablets, capsules, liquid injections, dry powder injections, lyophilized injections, and suspensions.

Which facility manufactures beta-lactam products?

Vadgas, Viramgam Unit 3 is identified as the beta-lactam manufacturing facility.

What is manufactured at the LVP facility?

The LVP facility is described as manufacturing IV solutions using PVC bottles, with FFS and Euro Cap bottle formats.

What is the stated FFS LVP capacity?

The supplied information states a capacity of 10 million FFS bottles per day.

What is manufactured at Vadgas Unit 6?

Vadgas Unit 6 is described as a manufacturing facility for nutraceuticals and food supplements.

The Taj Pharma Group manufacturing facilities setup comprises a diversified network of pharmaceutical production capabilities covering oral solid dosages, sterile injections, oncology products, beta-lactam antibiotics, large-volume parenterals, topical products, nutraceuticals, and food supplements.

The Sarigam GIDC facility provides high-volume formulation manufacturing, while the Kalgam Village, Valsad plant supports injectable production. Specialized facilities at Vadgas, Viramgam address general injectables, oncology, beta-lactam products, tablets, capsules, and nutraceuticals. The dedicated LVP infrastructure further expands the manufacturing portfolio into high-volume IV solutions.

By organizing production into specialized facilities and manufacturing blocks, Taj Pharma has developed an infrastructure capable of supporting diverse pharmaceutical product requirements and large stated production volumes.

The facility capacities, locations, certifications, approvals, and manufacturing capabilities described above are based on the supplied manufacturing reference information. Current regulatory status and individual facility claims should be confirmed against applicable official documentation before publication or commercial use.